Clinical cancer research translates basic science concepts into clinical reality. The Columbus Community Clinical Oncology Program is a consortium of 15 hospitals covering 36 counties in 3 states dedicated to the accrual of patients with all forms of cancer into clinical trials. The Columbus CCOP fulfills the mission of the CCOP program by providing the most relevant trials to our physicians, nurses and patients along with extensive educational opportunities for cancer health professionals and a framework for multispecialty collaboration throughout central and southeastern Ohio. Building on past successes, the Columbus CCOP will concentrate on a number of initiatives. The administrative organization of the CCOP has been recently restructured to improve efficiency and accuracy of data collection. New processes are in place and data quality assurance has improved. The success of this initiative will be further assessed over the next few years and adjustments made to the quality control process. Another goal is to increase the availability of clinical trials to more community physicians, especially in the underserved Appalachian areas of the state. Increased participation in clinical research will enhance the quality of oncologic care delivered to patients, thereby reducing mortality and morbidity. Recruitment efforts are currently underway and will continue with a view to expansion of our coverage area so that all cancer care physicians and their patients in Central and Southeastern Ohio have access to clinical trials through the Columbus CCOP. The CCOP also plans to involve radiation oncologists and community surgeons via specific research base trial participation (RTOG and hopefully, ACOSOG). The Columbus CCOP is an experienced organization and we are dedicated to working closely with the NCI to move the science of oncology to new levels of achievement.
Participation in clinical trials improves the skills of community oncologists and this translates to enhanced quality of care as national guidelines incorporated in all trials are followed. As a major contributor to the CCOP program, the Columbus CCOP will improve prevention of cancer, treatment outcomes, and overall survival from cancer in our population.
|Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585|
|Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440|
|Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8|
|Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64|
|Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51|
|Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8|
|Deininger, Michael W; Kopecky, Kenneth J; Radich, Jerald P et al. (2014) Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 164:223-32|
Showing the most recent 10 out of 151 publications